The early prostate cancer program: Bicalutamide in nonmetastatic prostate cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 361-369

  Iversen, Peter ^a   Roder, Martin Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adjuvant hormonal therapy; Bicalutamide; Nonsteroidal antiandrogen; Overall survival; Prostate cancer; Radical prostatectomy; Radiotherapy; Watchful waiting

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST; GOSERELIN; PLACEBO; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST DISEASE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER DYSFUNCTION; MASTALGIA; ORCHIECTOMY; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK REDUCTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NITRILES; PROGRAM EVALUATION; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOSYL COMPOUNDS;

EID: 45249098453     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.361     Document Type: Article

References (37)

1. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1285-1290 (2005).
2. Roach III M, Lu J, Pilepich MV et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 47(3), 609-615 (2000).
3. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 352(19), 1977-1984 (2005).
4. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7(6), 472-479 (2006).
5. Johansson J-E, Holmberg L, Johansson S, Bergström R, Adami H-O. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277(6), 467-471 (1997).
6. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 360(9327), 103-108 (2002).
7. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J. Urol. 164(5), 1579-1582 (2000).
8. English KM, Steeds R, Jones TH, Channer KS. Testosterone and coronary heart disease: is there a link? QJM 90(12), 787-791 (1997).
9. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106(3), 581-588 (2006).
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24(27), 4448-4456 (2006).
11. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 24(24), 3979-3983 (2006).
12. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin. Cancer Res. 10(22), 7575-7582 (2004).
13. Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int. 96(1), 48-53 (2005).
14. Basaria S, Lieb J, Tang AM et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin. Endocrinol (Oxf.) 56(6), 779-786 (2002).
15. Berruti A, Dogliotti L, Terrone C et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation. J. Urol. 167(6), 2361-2367 (2002).
16. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J. Urol. 171(6 Pt 1), 2272-2276 (2004).
17. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J. Urol. 175(1), 136-139 (2006).
18. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer effects on bone mineral density and body composition. J. Clin. Oncol 22(13), 2546-2553 (2004).
19. See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer program: demography. Urol Oncol 6(2), 43-47 (2001).
20. See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J. Urol. 168(2), 429-435 (2002).
21. Wirth MP, See WA, McLeod DG et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol. 172(5, Part 1 of 2), 1865-1870 (2004).
22. McLeod DG, Iversen P, See WA et al. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int. 97(2), 247-254 (2006).
23. Wirth M, Tyrrell C, Delaere K et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer trial 24 at a median 7 years' follow-up. Prostate Cancer Prostatic Dis. 10, 87-93 (2006).
24. Iversen P, Johansson JE, Lodding P et al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years. Scand. J. Urol. Nephrol. 40(6), 441-452 (2006).
25. McLeod DG, See WA, Klimberg I et al. The bicalutamide 150 mg Early Prostate Cancer Program: findings of the North American trial at 7.7-year median followup. J. Urol. 176(1), 75-80 (2006).
26. Smith JA Jr, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 54(Suppl. 6A) 8-14 (1999).
27. See WA, Tyrrell CJ. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. J. Cancer Res. Clin. Oncol. 132(Suppl. 1), S7-S16 (2006).
28. Tyrrell CJ, Payne H, Tammela TL et al. Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int. J. Radiat. Oncol. Biol. Phys. 60(2), 476-483 (2004).
29. Van Poppel H, Tyrrell CJ, Haustermans K et al. Efficacy and tolerability of radiotherapy as treatment for bicalutamide-induced gynaecomastia and breast pain in prostate cancer. Eur. Urol. 47(5), 587-592 (2005).
30. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamicle-incluced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 8(1), 75-83 (2005).
31. Boccardo F, Rubagotti A, Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin. Oncol. 23(4), 808-815 (2005).
32. Fradet Y, Egerdie B, Andersen M et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur. Urol. 52(1), 106-114 (2007).
33. Van Poppel H. Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur. Urol. 52(1), 115-(2007).
34. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169(6), 2008-2012 (2003).
35. Smith MR, McGovern FJ, Zietman AL et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345(13), 948-955 (2001).
36. Iversen P, Tammela TLJ, Vaage S et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group study no. 6. Eur Urol 42(3), 204-211 (2002).
37. Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology 4(1), 5-13 (2004).